T HE PLASMINOGEN activator (PA) system is responsible for the degradation of intravascular blood clots,' while also contributing to extracellular proteolysis in a wide variety of physiological (eg, tissue remodeling, cell migration, wound healing, angiogenesis, trophoblast implantation, ovulation, and fetal development) and pathological (eg, acute and chronic inflammation, preeclampsia, intrauterine growth retardation, tumor invasion, and metastasis) processes.24 Rapid progress in the understanding of the role of the PA system in these processes has been obtained recently by studying transgenic mice deficient in t-PA, U-PA, plasminogen activator inhibitor-l (PAI-1) or combined t-PNu-PA.' These studies have confirmed the significant role of the PA system in fibrin clot surveillance, wound healing, tissue remodelling, and arterial neointima formation and seems to be required for normal health and survival.
2 was isolated independently by several It encodes a protein of 415 amino acids, having a predicted unglycosylated Mr of 46'543, close to that reported for the 47 kD cytosolic form of PAI-2. The N-terminus of the PAI-2 protein was blocked and could not be directly sequenced. However, the first AUG encodes a methionine at a position that corresponds to the start of helix A of alphal-antitrypsin26 and sequencing of metabolically labeled PAL2 confirmed that the protein starts with this methionine:' suggesting that secreted PAI-2 has no N-terminal signal peptide.
The reactive center (arg-380 and thr-381) was identified by direct sequencing of the PAL2 cleavage product after reaction with u-PA2' and is in agreement with the arg-specificity of PAS that activate plasminogen by cleavage of an arg-Val bond. PAI-2 has three potential N-linked glycosylation sites (am-75, asn-115, and asn-339), which all appear to be occupied in glycosylated PAI-2.3' Two common variants of PAL2 have been described differing at three positions: one having asn-120, asn-404, ser-413 (type A), the other having asp-120, lys-404, cys-413 (type B), both of which have been identified in U-937 cell^.'^"^^^^ The extra cysteine in Type B PAI-2 may mediate dimerization" or the formation of disulfide bridges between active PAL2 and other placental proteins, such as ~itronectin.'~.'~ The presence of transglutamination sites (gln-83, gln-84 or gln-86) provides a mechanism for the localization or concentration of both types of PAI-2 to cellular or extracellular s t r u c t~r e s .~~-~~ These sites are blocked by glycosylation at a~n -7 5 .~~
The cDNAs for mouse and rat PAI-2 have been isolated (mouse PAI-2: Belin, embl-X16490 and rat PAI-2: Grundmann; embl-X64563). They encode proteins that are 80% KRUITHOF, BAKER, AND BUNN homologous to human PAI-2. The second and fourth cysteine residues of human PAI-2 are also present in both mouse and rat PAI-2, so the other cysteines may not be required for biological activity. Species differences in glycosylation sites may also exist.
Relation of PAI-2 to other members of the serpin family. Serpins are single chain molecules that contain a conserved structure of approximately 370 amino acids. Most serpins function as protease inhibitors, but some have alternate functions such as hormone transport or blood pressure regulat i~n .~~ PAL2 was shown to share a striking degree of homology with chicken ovalbumin, with respect to amino acid identity, the absence of an N-terminal signal sequence, and an identical gene s t r u c t~r e .~~*~~~" In contrast, PAL2 is phylogenetically quite distant from PAI-1, despite the close target enzyme specificity. Recently, an ovalbumin-serpin family was proposed," with the following members recognized to date: ovalbumin, the chicken gene Y product, PAI-2, squamous cell carcinoma antigen," leukocyte elastase inhibitor~:"-~' placental thrombin inhibit~r?~ maspin, an inhibitor of tumor invasion,44 two limulus intracellular coagulation inhibitor^,^' and a cowpox virus-encoded erp pin^^ that inhibits interleukin-l/3 converting enzyme.47 The ov-serpins are characterized by a high degree of amino acid identity (for a comparison of amino acid sequences of PAI-2 with the ovserpins and alpha-l antitrypsin see:48), their identical gene structure, and their lack of an N-terminal signal sequence leading to a mainly intracellular location. The function of most of these proteins remains to be established.
Target enzyme speciJcity of PAI-2. PAL2 is an efficient inhibitor of U-PA (rate constant lo6 M" S-') and two chain t-PA (2.10' M" s ' ) , '~" '~~~ albeit slower than PAI-l, by a factor of 10 and 50 times, respectively." Compared with PAI-1, it is a poor inhibitor of single chain t-PA (10' M S -' v lo7 M" S-l), which makes it unlikely that PAI-2 contributes to the inhibition of single chain t-PA in vivo.'8.'' Also, fibrin-bound t-PA appears to be protected from inhibition by PAI-2." Secondary interaction sites are likely to contribute to the interaction of PAI-2 with U-PA, because a U-PA mutant lacking the basic region 179 to 184 (RHRGGS), as well as a phosphorylated form of U-PA, react more slowly with PAI-2 than wild-type u-PA.'"'~ PAL2 forms bimolecular 1: I sodium dodecyl sulfate (SDS) stable complexes with u-PA and t-PA, which after treatment with nucleophilic agents, yield intact enzyme and inhibitor cleaved at the reactive P1-PI ' bond. '8,2s This suggests that the mechanism of PAI-2 action follows the general model for serpin action. 36 Plasminogen activation by U-PA occurs preferentially at the cell surface through binding of U-PA and plasminogen to specific receptors. Receptor-bound U-PA is still efficiently inhibited by PAL2 and PAI-1
The single chain proenzyme form of U-PA does not form SDS stable complexes with PAI-2, but is able to inhibit complex formation of PAI-2 with active u-PA.'~ Although PAL2 is able to inhibit several other serine proteases, it is unlikely to be a major regulator of their activity. PAL2 is an inhibitor of acrosin (3.3 X lo4 M-' S-'), but its concentration in seminal plasma is much lower than that of PAI-3/activated protein C inhibitor (0.2 nmolL v 5,300
For personal use only. on August 18, 2017. by guest www.bloodjournal.org From nmol/L), which is equally efficient (3.7 X lo4 M" s").~' PAI-2 inhibits plasmin (10' M" S") poorly in comparison to a-2-antiplasmin (IO7 M" S -' ) , which is present at much higher concentrations. PAL2 is unable to inhibit glandular and plasma kallikrein or thrombin, even in the presence of heparin."
CELLULAR TARGETING OF PAI-2
Facultative translocation of PAI-2. The principal known target proteases of PAI-2, U-PA, and t-PA are mediators of extracellular proteolysis. Surprisingly, PAI-2 was found mainly intracellularly in almost all cell types studied to glycosylated PAL2 in cell-conditioned medium implies that there is also secretion via the regular secretory pathway. Under certain conditions, glycosylated PAI-2 may represent a significant part of total PAI-2, which suggests that the cellular targeting of newly synthesized PAI-2 can be modulated.3'.62 The 47-kD form of PAI-2 has also been detected in large amounts in cell-conditioned medium, particularly after prolonged exposure of U-937 cells to phorbol ester." Cell death (tissue necrosis or apoptosis) may be one route enabling the 47-kD form of PAL2 to reach the extracellular environment. The possibility of other mechanisms leading to the release of 47 kD PAL2 from viable cells cannot be excluded, but hard data are lacking at present. Because both forms of PAI-2 are detected in pregnancy p l a~m a , h~,~ an in vivo mechanism should exist by which the intracellular form of PAI-2 reaches the circulation.
The cellular targeting of PAI-2 is unusual. Normally, secretory proteins are transported and processed through the Golgi stack to the plasma membrane either directly (constitutive secretion) or via storage granules (regulated secretion). The presence of both cytosolic and secreted PAI-2, suggest a peculiar signal sequence. Studies on the mechanism responsible for the differential cellular targeting of PAL2 showed that both 47 kD and 60 kD PAI-2 are encoded by a single mRNA species and use the same AUG start codon." These findings, as well as the position of the N-terminal methionine within the three dimensional structure of serindicate that PAI-2, like ovalbumin, has an internal signal sequence and that the proposed dual localization may be the result of a facultative translocation into the secretory pathway. A fusion protein containing the PAI-1 signal peptide was efficiently translocated in vitro and secreted by Chinese hamster ovary (CHO) cells," indicating that the PAI-2 protein contains no structures interfering with translocation. By analogy to studies on the internal signal sequence of ovalbumin, the role of hydrophobic regions in alpha helix A (amino acids 4 to 16) and alpha helix B (amino acids 25 to 46) was investigated. Both regions were essential for translocation of PAI-2 and the efficacy of translocation was enhanced by increasing the hydrophobicity of these reg i o n~.~~.~~ Although PAI-2 has been detected proximal to the cell surface,6s.6g no published studies have addressed the possibility that PAI-2 may be targeted to the cell surface. These are critical studies that need to be done because the target for date.19-2' .30.5Y-61 H owever, the presence of trace amounts of PAI-2, U-PA, exerts many of its physiologic functions bound to U-PAR.
TISSUE DISTRIBUTION OF PAI-2 IN VIVO
Initially it was believed that PAI-2 expression was limited to monocytes/macrophages and to placenta and that PAI-2 was consistently found only in pregnancy plasma. However, more recent findings suggest a wider tissue distribution, raising questions concerning the role(s) of PAI-2.
Assays. An appreciation of the tissue distribution of PAI-2 requires consideration of the assays employed. Antigen assays in tissue extracts or body fluids measure total PAI-2 and should be complemented with immunohistochemical analysis (or in situ hybridization) to determine the location of PAL2 and identify the cell types expressing PAI-2. The most commonly used PAL2 enzyme-linked immunosorbent assays (ELISAs) have a sensitivity in the range of 3 to 5 ng/mL,"." but do not distinguish free from PA-complexed PAI-2 or glycosylated from nonglycosylated PAI-2 and are not sensitive enough to measure €' AI -2 in most normal human plasmas.
Many alternate assays may give useful information. Among these are reverse zymography (using nondenaturing gels7') or chromogenic substrate assays, which are both dependent on the inhibition of U-PA acti~ity.'~,''~~' Glycosylated and nonglycosylated PAL2 have been distinguished by western blotting or by electrophoretical analysis of complexes of PAI-2 with radioiodinated u-PA.'"ly~'' In contrast to PA-PAI-1 complexes, it is not possible to detect U-PA/ PAI-2 complexes by direct fibrin or casein ~ymography.~~ The 2.0-kb PAI-2 mRNA can be detected by Northern blot analysis or by in situ hybridization.27~28~6'~7"7h Finally, it is important to note that cultured cells isolated from normal or diseased tissue may not express PAI-2 and respond to stimuli the same way they do in their in vivo environment.
Blood plasma. PAI-2 levels in plasma are normally below detection limit. However, under certain conditions, such as pregnancy and in some myelomonocytic leukemias PAI-2 is consistently detected in plasma (see below).
Monocyte/macrophages. Plasminogen activator inhibitory activity was described in human monocytes and macroare now known to produce both PAI-I and PALLx4
Gingival crevicular juid. PAI-2 has been detected in human gingival crevicular fluid and in whole saliva.".R6 PAI-2 levels in human gingival crevicular fluid (2 to 8 mg/L) were one order of magnitude higher than those in pregnancy plasma (0.2 to 0.4 mg/L; see below). Interestingly, the major PA present in gingival crevicular fluid is t-PA; its activity was quenched by PAI-2. By immunoblot analysis, glycosylated PAI-2 was detected, which suggests secretion of PAI-2 via the normal secretory pathway and a possible role of glycosylated PAI-2 in preventing tissue destruction. The proximity of PAI-2 to t-PA rather than U-PA is reminiscent of skin (see below).
Fibroblasts andfibroblast-like cells. PAI-2 is expressed in fibroblast-like cells from a variety of sources, including fetal lung ~e l l s ,~~~~' f o r e~k i n ,~' ,~~ human synovial explant~,~'.'' and bone marrow ~troma.~' In unstimulated human endothelial cells,  PAI-2 expression is low or undetectable, but markedly  increases after inflammatory stimuli (see below) . Cultured vascular smooth muscle cells express PAI-2 in addition to PAI-l and protease n e~i n .~~.~~ In these cells, most PAI-2 was cell-associated.
Other nondisease occurrence of PAI-2. PAI-2 has also been detected in human omental95 and pleural96 mesothelial cells and in microglia,97 which are brain representatives of the mononuclear phagocytic system. Human cumulus and granulosa-luteal cells possess PAL2 mRNA, as well as PAI-1 mRNA, although these are regulated differently by epidermal growth factor (EGF) and human chorionic gonadotropin (hCG), PAL2 being more inducible than PAI-1. The marked induction of PAI-2 in these cells suggests a role in controlling postovulatory proteolysis of the follicular wall." Furthermore, PAI-2 was detected in seminal plasma,58 but its target enzyme was not established.
Taken together, it is clear that the distribution of PAL2 is much more widespread than initially thought. The predominant form in a number of cell types appears to be cell-associated and of low-molecular weight, while the high-molecular weight, glycosylated form has been detected in pregnancy plasma and gingival crevicular fl~id.6',@.~',~~ The occurrence of PAI-2 in several tissues along with t-PA suggests that it may also play a role in inhibiting t-PA.
EXPRESSION AND REGULATION OF PAI-2 BIOSYNTHESIS IN VITRO
The regulation of PAL2 expression has been extensively studied in primary cultures of monocytes, fibroblasts, kera- (Table 2) , which may act in a cell-type and differentiation stage-dependent fashion. Furthermore, the interaction between various signal transduction pathways, which may be synergistic or antagonistic, provides additional regulatory possibilities. (Table 3 ) Regulation of PAL2 is often at the level of gene t r a n s c r i p t i~n ,~~~~~ but may also be via a change in mRNA stability, possibly mediated by AU rich sequences in the 3' untranslated region of PAL2 mRNA.'y Normally PAI-2 mRNA has a half-life of 30 minutes to 2 hour s: '.
'@' but it was more stable in monocyte-like cells stimulated by lipopolysaccharide (LPS)," by phorbol ester, and by CAMP,"' whereas dexamethasone increased the rate of PAI-2 mRNA decay in tumor necrosis factor (TNF)-stimulated melanoma cells.90 One should bear in mind that PAI-2 expression may be cell cycle-dependent" and that the effect of a specific factor does not necessarily imply a direct action on PAI-2 gene transcription or mRNA stability, but may also be indirect (eg, as a consequence of differentiation or by induction of factors like TNF or interleukin-l (IL-l), which are powerful inducers of PAI-2).
LPS. Macrophage/monocyte-like cells respond to LPS by an increased expression of tissue factor, of cell surface associated U-PA, and of PAI-2 and PAL1 .27~76~7y~102-10H Th e LPS-mediated induction of PAL2 expression in monocytes was inhibited by Lipid X, a biosynthetic precursor of LPS,Io4 by IL-4, by dexamethasone, and by transforming growth factor-beta and potentiated by interferon-gamma.'06.'07 LPS also induced PAI-2 in human me~othelial~~ and endothelial cells.*' Phorbol ester. Phorbol myristate acetate (PMA), a known inducer of differentiation of myelomonocytic cells towards a macrophage phenotype, is a powerful inducer of PAL2 expression in monocytes, macrophages, and myelomonocytic cell lines (eg, U-937, HL-60, K562, and PL-21 PAI-2 is constitutively expressed in aging human diploid fibroblasts, but is undetectable in young fibroblasts." This may be due to an autocrine effect of IL-1, which is constitutively expressed in aging fibroblasts. The cyoclooxygenase inhibitors indomethacin and naproxen potentiated the action of IL-1 in enhancing PAI-2 production?' In human synovial fibroblasts, dexamethasone, and transforming growth factor-,Ll inhibited the IL-1-mediated induction of PAI-2.713y'
Other cytokines and growth factors. The expression of PAI-2 in monocytes/macrophages was increased by various other cytokines and growth factors, eg, IL-2,"' interferon gamma,'" macrophage and granulocyte-macrophage colonystimulating factor^,'^.'^^ while it is decreased by transforming growth fa~tor-,Ll."~ EGF induces PAI-2 in A431 epidermoid car~inoma''~ and in human granulosa luteal cells.98
CAMP. The effect of cAMP inducing agents is cell-type specific. In macrophage/monocyte-like cells, an increase of cAMP stimulates PAI-2 production and potentiates the effect In contrast, in human HT-1080 fibrosarcoma cells, the PMA-mediated induction of PAI-2 is antagonized by CAMP.''~ Also, in SK-MEL-109 melanoma cells cAMP antagonizes the TNF-mediated induction of PAI-2.'I5 Retinoic acid, vitamin 0 3 , and calcium ionophore. In myeloid leukemia cell lines, retinoic acid induces differentiation towards a granulocytic phenotype. Retinoic acid alone had no effect on PAI-2 and U-PA expression in HL-60 and U-937 cells, but potentiated the PMA-mediated induction of these proteins.'0y.1'6 In human promyelocytic NB4 cells, induction of differentiation by retinoic acid toward a granulocytic phenotype led first to a rapid increase in U-PA activity, which was thereafter counteracted by an increased production of PAI-1 and PAI-2.'27 In U-937 cells, calcitriol induced a reduction of PAI-2 and an increase in U-PA mRNA, whereas the calcium ionophore A23 187 had the opposite effect."' Glucocolticoids. Various other stimulators. In monocytes, PAI-2 expression was increased after infection with Dengue virus'3o and by treatment with D-dimer, a fibrin degradation product.'" In fibroblasts, PAI-2 is a serum-inducible gene." In human keratinocytes, dioxin induces a strong increase of IL-1 and of PAI-2.I3* Transformation of rat-l cells with the oncogenes v-src and EJras augments the expression of PAI-2.I3' Finally, two recent studies suggested a potential link between PAI-2 expression and hypertension or atherosclerosis: angiotensin I1 induced more than a 10-fold increase in PAL2 mRNA in rat microvessel endothelial cells and rat aortic smooth muscle cells,134 whereas very low-density lipoproteins and lowdensity lipoproteins enhanced PAI-2 expression in cultured human monocytes-macrophages.'3s
Differentiation of muscle cells. Human myogenic satellite cells proliferate in vitro and differentiate into multinucleated myotubes. PAI-2 is undetectable in proliferating myogenic cells, but its expression increases markedly just before myoblast fusion and remains high for at least 22 days.'36 During differentiation of these cells, U-PA activity in cell extracts increases by 40-fold. Activity blocking antibodies to U-PA have no effect on myogenic satellite cell proliferation, but inhibit myotube formation. This suggests a regulatory role for PAI-2 in myotube formation.
GENE STRUCTURE OF PAL2
The PAI-2 gene (designation: PLANH2) is located on chromosome 18q2 113.27332*1373'38 The chromosomal region of PAI-2 is relatively well characterized and contains a serpin cluster. Within 300 kbp centromeric from the PAI-2 gene, three other ov-serpins are found: the two squamous cell carcinoma antigen genes and the maspin gene.'39 Furthermore at 600 kbp centromeric lies the bcl-2 p r o t o~n c o g e n e , '~~~'~ a major regulator of apopto~is.'~' Deletions at or near this region are observed in a large proportion of colorectal tumors, associated with the DCC (deleted in colon cancer) gene,I4* and in B-cell lymphoma and familial expansile ost e o l~s i s . '~~ Whether any of these (or other) pathologies are linked to a deficiency of PAI-2 or one of the other inhibitors in the 18q21.3 serpin cluster remains to be established. Restriction fragment length polymorphisms have been identified using EcoR1 (frequencies 0.33f0.67) and Bcll (0.261 0.74).'43.'44
The PAL2 gene contains 8 exons and 7 introns and has the same structure as the ovalbumin gene and the two squamous cell carcinoma antigen gene^.^'*'^.'^' Its transcription initiation site is situated between 22 to 25 bp3',37~'45 downstream of a TATAAAA consensus sequence. The sequence of two kbp of the 5' flanking region and of the 65-bp first exon, as well as a restriction map of 8 kbp surrounding the transcription initiation site, are k n~w n . "~'~~~'~ The PAI-2 promoter contains two alu repeat sequences (between -1390 and -1 1 0 0 and between -870 and -580).'45 Several regulatory elements have been identified in the PAL2 promoter by homology analysis to known regulatory sequences, by reporter gene assays using deletion and site For personal use only. on August 18, 2017. by guest www.bloodjournal.org From specific mutants, by nuclease protection analysis, by band shift analysis, and by southwestern blotting. Two closely spaced AP-1 like elements (at -116 to -97) and a CRElike element (at -189 to -182) are essential for basal gene transcription and for the PMA-mediated induction of the PAI-2 gene.'47 A retinoic acid receptor element half-site linked to a glucocorticoid response element half-site (at -1659 to -1620) may mediate the retinoic acid response of the PAI-2 gene.14* The region around -1150 is homologous to a dioxin response element and might mediate the response of PAL2 to dioxin."* An enhancer region, influencing basal transcription and PMA induction was identified between -3.3 kb and -5.1 kb, whereas a suppressor element appears to be present between -1.3 and -2.7 kb.I4' By Southwestern blotting a protein was identified with a size similar to that of an interferon-gamma activated DNA binding element of which homologous sequences are found at -3.4 and at -4. I kb.'46
PAI-2 IN PREGNANCY
Normal pregnancy. Plasma concentrations of PAI-2 gradually increase during pregnancy from below detection limit (<5 ng/mL) to a maximum of 250 ng/mL at Also increases of t-PA, U-PA, and PAI-I occur. As a result of these changes PA activity measured in pregnancy plasma is decreased, which may be due to a reaction of t-PA with excess PAI-I, rather than with PAI-2.I5' Although pregnancy plasma contains mainly 60 kD PAI-2," some 47 kD PAI-2 is also observed.h3 Cord blood contains mainly 47 kD PAI-2, while amniotic fluid has equivalent amounts of both.h4 Additionally, two PAL2 activity bands were detected in pregnancy plasma by reverse zymography, a major one at 75 kD and a minor one at 130 kD."' Several lines of evidence indicate that PAI-2 in pregnancy plasma is produced in the placenta. Thus, PAI-2 concentrations in decidual and placental tissue at gestational week 8 to 12 are 50 times higher than those in term pregnancy plasma.'5s Furthermore, PAL2 protein and mRNA were detected in placental villous syncytiotrophoblasts, whereas PAI-I was detected mainly in epithelial cells of the chorioamniotic membrane and only weakly in syncytiotrophoblasts.1sh~'5x PAI-2 concentrations remain elevated for several days postpartum, while PAI-I concentrations return to normal within a few hours. This finding further supports the idea that different cell types are responsible for the increase of PAI-I and PAL2 in pregnancy plasma and suggests that the placenta is also the principal source of elevated plasma PAI-1. The persistence of PAL2 for several days postpartum may derive from decidual or placenta remnants that remain attached to the uterine wall. PAL" may contribute to the regulation of the invasive potential of trophoblasts, which invade and remodel uterine tissues. Thus, U-PA expression is highest in the invasive intermediate trophoblasts and in the syncytiotrophoblasts, which also express PA1-2.6y~'s6~'sy The presence of an excess of PAL l and PAL2 in the conditioned medium of these cells ensures that U-PA activity is only found at the cell surface. The observation in placenta extracts of PAL2 cleaved at the reactive center is in accordance with a local regulatory role for PAI-2."" term,h3,h4,149-l.53 PAIS are not only released into the blood stream but also into the amniotic fluid." Thus, PAI-2 antigen levels in amniotic fluid increased from 70 ng/mL (first trimester) to 170 ng/mL (third trimester), whereas PAI-I increased from 190 ng/mL to 640 ng/mL."' PAI-2 concentrations in fetal plasma are below detection limit. Thus, fetal tissue does not appear to contribute to PAI-2 in maternal plasma.'62 Also PA1 activity (measured by an assay sensitive for PAI-I, but not PAI-2) was much lower in fetal plasma (average: 2.0 U/mL) than in control plasma (9.2 U/mL) and in pregnancy plasma (up to 30.7 U/mL). These findings suggest that the placental production of PAI-1 and PAI-2 is selectively directed toward the maternal circulation.
Preeclampsia or intrauterine growth retardation. These complications of pregnancy show clear modifications with respect to normal pregnancies of the same gestational age and are characterized by increased plasma PAIL1 and t-PA levels and decreased plasma PAI-2 and U-PA as compared with uncomplicated pregnancies.153~'6"7" However, in patients with intrauterine growth retardation without preeclampsia, PAI-2 levels are low and PAL1 levels normal, whereas in patients with preeclampsia without intrauterine growth retardation, PAI-2 levels are normal and PAL 1 levels elevated. These results suggest that elevated PAI-I is a predictive marker for pree~lampsia'~' and that reduced PAI-2 is a marker for a decreased placental function and intrauterine growth retardation.'hS~'hX~172 By using the antigen ratio of PAI-1 to PAI-2, a better discrimination between preeclampsia and normal pregnancy was obtained, the ratio in normal pregnancy being on average 0.6, while that in preeclampsia was 2.5."'
PAI-2 IN CANCER
Mortality from malignancy is primarily due to the capacity of tumor cells for invasion and early spread to vital organs whose function cannot be compromised. The ability of cells derived from solid tumors to demonstrate invasive behavior and metastasize has been correlated with the expression of various cathepsins, metalloproteases (eg, collagenase IV) and components of the plasminogen activation cascade, in particular u-PA.'~'"~' Although U-PA has as one of its major functions tissue proteolysis and extracellular matrix remodeling, other functions like activation of mitogenic proteins and growth factors may be equally important in the context of cancer growth and spread. Clinical studies strongly support the plethora of in vitro experimental data, which implicate U-PA in tumor metastasis. Firm correlations exist between elevated antigen levels of U-PA and of PAI-1 in tumor extracts (eg, ovarian, breast, colon, and lung cancer) and higher incidences of cancer relapse, shorter overall survival, and increased degree of i n v a~i o n .~~~"~~ Despite the abundance of literature implicating U-PA in metastasis, few studies have addressed the role(s) of endogenous PAI-2 either in solid tumors or leukemia.
Leukemia. PAL2 levels were found to be markedly increased in plasma and in leukemic cell extracts of patients with myelomonocytic leukemia (M4), acute monocytic leukemia (M5), some undifferentiated acute myeloblastic leukeFor personal use only. on August 18, 2017. by guest www.bloodjournal.org From mia, and in chronic myelocytic leukemia during blast critherapy, but may increase again during relapse.1x7 These data suggest that plasma PAL2 may be a marker for certain types of myelomonocytic leukemia and indicative of relapse. A proteolytically cleaved, but still active, form of PAI-2 was detected in myeloid leukemia cell lines driven to apoptosis and in bone marrow mononuclear cells from some acute and chronic myeloid leukemic patients.'" This form should be studied for its usefulness as a marker for the further subclassification of myeloid leukemias or for analyzing certain intracellular changes associated with apoptosis in PAL2 producing cells.
Breast cancer.
Concentrations of PAL2 were found to be higher in extracts of breast cancer than of benign breast turn or^.'^'.'^^ In two recent studies, the prognostic value of PAL2 in breast cancer was r e p~r t e d . "~. '~~ PAL2 concentrations in carcinomas with lymph node involvement were lower than in carcinomas without, whereas for PAI-I, the opposite was found. Low PAI-2 levels in tumor extracts were associated with a shorter relapse free survival, metastatic disease free survival, and overall survival. A subgroup, characterized by high levels in tumor extracts of U-PA and PAI-I and low levels of PAI-2 was identified, which had a very poor prognosis. Multivariate analysis identified node involvement, macroscopic tumor size, and PAI-2 concentration as significant prognostic variables.'8s
Endometrial and ovarian cancer.
The relationship between PAI-2 and the stage of endometrial disease has been in~estigated."~"~~ PAL2 was detectable only in some normal, but in all malignant endometrial homogenates. Its concentrations were higher in later stage disease as compared with early stage and present at higher concentrations in highly invasive malignant tumors than in less invasive tumors. No significant correlation was found between estrogen receptor concentration and PAL2 antigen.
In ovarian cancer, high levels of PAI-2 indicated a poor prognosis in International Federation of Gynecology and Obstetrics (FIGO) Stage 3 patients.'97 Lung cancer. Both PAI-2 and U-PA antigen levels were found to be higher in extracts from pulmonary adenocarcinoma than from normal tissue; low PAI-2 or high U-PA levels discriminated cases with lymph node involvement from node negative cases.198.1qy PAL2 was detected in the normal epithelial layer and within interstitial and alveolar macrophages, whereas tumor cells stained more weakly.2",2n' Cells of the peripheral cords of squamous cell carcinomas were inconsistently positive for PAI-2, whereas large-cell carcinomas were PAI-2 negative.2m
Melanoma. The expression of U-PA, U-PAR, PAI-1, and PAL2 has been examined in the progression from common nevocellular nevi, dysplastic nevi, early primary melanoma, and advanced primary melanoma through melanoma metastases."' U-PA was found in both stromal cells and in tumor cells at the invasive front, the U-PA receptor and PAI-2 occurred in tumor cells, while PAI-1 was in the extracellular matrix surrounding tumor cells. Similar patterns emerged from in situ hybridization. In one study, U-PA, U-PAR, PAI-1, and PAL2 were not seen in either benign or early stage sis.187-189 Plasma PAI-2 levels normalize rapidly during disease, but appear in advanced primary melanoma and in metastatic However, another study suggested that upregulation of the U-PA gene is an early feature of melanocyte transformation and that unbalanced enzymehnhibitor activity is associated with the malignant phenotype."' Gastrointestinal cancers. In gastric cancer, tissue levels of PAI-2, U-PA, and PAL1 were found to be higher than in control tissues. Tumors with metastasis to remote lymph nodes were characterized by higher PAL1 and lower PAI-2 Most of human pancreatic carcinomas expressed PAI-2, U-PA, and PAI-l .*Os PAL2 expression was significantly lower in carcinomas with peritoneal metastasis. Elevated PAL2 was associated with a significantly higher survival than negative or low PAI-2 levels. Many studies have reported increased levels of U-PA in colorectal t~m o r s , *~. *~~ but few have correlated U-PA levels with advancing Duke's staging.zn8 Low t-PA and high u-PNt-PA antigen ratios in normal mucosa and high U-PA and PAL2 antigen levels in carcinomas are prognostic for a poor overall survival of patients with colorectal cancer.*07 Immunohistochemical analysis showed that PAI-2 and U-PA were expressed by interstitial dendritic cells, macrophages, and fibroblastic cells, while colon carcinoma cells and liver metastases were negative.z~.zo9.210
The chromosomal localization of the PAI-2 gene at or near a region commonly deleted in sporadic colorectal tumors (see "Gene Structure") warrants a more detailed study on possible deletions of the PAI-2 gene in colon cancer or other malignancies associated with deletions of chromosome 18q21.
PAI-2: Inhibition of cancer cell invasion and metastasis. A number of steps involved in metastasis are sensitive to inhibition of U-PA activity either by PAIS or by inhibitory antibodies. The recent availability of substantial amounts of recombinant PAL2 has allowed for this serpin to be evaluated as a potential inhibitor of cell migration and tumor cell invasion. Exogenously added PAI-2 inhibited the plasminogen-dependent degradation by cancer cells of the basement membrane components collagen, proteoglycan, and glycoprotein~.~~.*'' Also, PAL2 inhibited extracellular matrix (ECM) degradation by M24met human melanoma cells more effectively than tissue inhibition of metalloproteases type 2 (TIMP-2), especially in the early stages.*'* Suramin, a polysulfonated naphthylurea compound, enhanced PAI-2 production and suppressed U-PA production by human renal cell carcinoma cells while inhibiting metastasis of these tumor cells after renal subscapular implantation in nude
The role of PAL2 was further studied using stably transfected HT-1080 clones. Expression of PAI-2 inhibited receptor bound U-PA activity and decreased extracellular matrix degradation by the fibrosarcoma cells. The PAI-2 expressing cells did not penetrate multilayers of smooth muscle cells in vitro while retaining tumorigenicity in nude mice.*14 In agreement with the idea that uncontrolled cellsurface plasminogen activation contributes to the morphologic differences between benign and malignant tumors, PAL2 expressing HT-l080 transfectants displayed a thickened collagenous-looking encapsulation, which was absent
A similar tumor encapsulation was observed using TIMP-2 transfected cancer cell^.''^ Human melanoma cells stably transfected with PAL2 and injected subcutaneously in severe combined immunodeficient (SCID) mice were also surrounded by a thick peritumoral capsule and had significantly less metastases in lung and lymph nodes than mock transfected control melanoma cells.'16 Intraperitoneal injection of PAI-2 resulted in a decrease of tumor mass after injection of xenografts of A43 1 cells in the peritoneal cavity of nude mice, whereas the plasmin inhibitor tranexamic acid had no beneficial effect."' Also, daily intratumoral injection of PAI-2 into DU-145 subcutaneous tumors in SCID mice significantly decreased tumor size.'" Obviously, the efficacy of PAL2 as an agent that might decrease tumor growth and metastasis, possibly by interfering with tumor angiogenesi~;'~ needs to be analyzed more carefully. In particular, the observation that PAI-2 decreased angiogenesis presumably through inhibition of U-PA expressed by endothelial cells in newly forming capillary sprouts'" should induce detailed studies on the effect of PAL2 on tumor angiogenesis.
PAL2 IN SKIN, SKIN DISEASES, AND WOUND HEALING
Differentiation of keratinocytes. The PA system has been implicated in the proliferation and differentiation of the normal human epidermis. Detailed studies using a combination of in situ hybridization, immunohistochemistry, and fssue extraction indicated that PAL2 is the predominant epidermal PA inhibitor being found throughout the normal epidermis, especially in the granular layers with diffuse and weak staining for PAL2 in cells in the lower and basal PAI-1 expression was mainly found in the least differentiated basal keratinocytes, while t-PA was detected in the suprabasal differentiated keratinocytes. PAI-2 mRNA and antigen were detected in most epidermal layers (being strongly present suprabasally and weakly in the basal layer).22' The levels of PAI-2 in keratinocytes increased on elevation of Ca concentration^.'^^ Taken together, these results suggest that PAL2 expression in keratinocytes is differentiation-dependent. Immunocytochemical localization experiments showed that most keratinocytes contain PAI-2, which in a subpopulation of more differentiated cells is resistant to detergent-extraction.'" Transglutaminase is expressed during keratinocyte differentiation and might mediate cross-linking to cell surface proteins of PAI-2,'4,'5 which was found to be located at or near the surface of keratinocytes." The finding that PAL2 becomes incorporated into the cornified envelope during terminal differentiation of the keratinocyte raises the possibility that PAI-2 may have an intracellular role associated with the terminal stage of keratinocyte differentiation.'*' The juxtaposition of PAL2 with t-PA is intriguing because PAL2 is generally regarded as an inhibitor of U-PA.
Pemphigus and psoriasis. Several studies observed elevated U-PA and t-PA in cutaneous disorders, which show blistering (acantholysis) resulting from the separation of basal epidermal cells from their basement membrane.*26-22' Also an increase in PAI-2 mRNA was observed in lesional skin of pemphigus vulgaris at the edge of the blister and the areaS,6R. [221] [222] [223] [224] In an organotypic coculture system, U-PA and adjacent intact epithelium, and in acantholytic cells in the blister cavity, suggesting that PAL2 may play a role in limiting epithelial damage.23" In accordance with this idea, PAI-2 prevented acantholysis in skin organ culture induced by either human or canine pemphigus IgG.2".232 In psoriasis, a chronic disease characterized by epidermal hyperproliferation and inflammation, an increase in U-PA in the basal keratinocytes and in the suprapapillary epidermis, and a greatly enhanced t-PA (protein and mRNA) expression in the suprabasal epidermis were observed.68~22h~22x~2~~~z~4 Psoriatic epidermis is similar to normal epidermis in that there is a strong PAI-2 expression in the more differentiated epidermal cells, but differs by an absence of PAI-2 in basal cells?' This is consistent with the observations230 described above for pemphigus and suggests that PAI-2 has a protective role in cutaneous pathologies that elicit abnormal wound healing patterns.
Wound healing. Several studies reported the presence of U-PA and U-PAR in keratinocytes in wound reepithelializaof elevated PA inhibitors after tissue injury to allow formation of a fibrin containing matrix, followed by elevated u-PA activity for fibrinolysis and replacement of the fibrin by granulation tissue. Urokinase may promote not only fibrin degradation, but also cell migration and mitogenesis.23"2'y There has been scant investigation of PAI-2 in wound healing. However, PAI-2 was elevated in the suprabasal layers of an organotypic skin culture system, which resembles wound healing22' and PAI-2 is one of a class of serum-inducible genes in fibroblasts, whose expression increases following mitogen or growth factor tim mu la ti on.^^ These models mimic the stimulation of connective tissue cells in wound healing and suggests that PAL2 may be involved in tissue repair. tion,233.2S5-2S7 Some observations suggested a general picture
INFLAMMATION, VARIOUS DISEASE STATES, AND APOPTOSIS
Injammation. The induction of PAL2 in monocyte-like cells and in fibroblasts by inflammatory mediators such as phorbol esters, LPS, IL-l, or TNF, its downregulation by antiinflammatory agents such as dexamethasone and IL-4 (see Table l ), and the finding that most cell types expressing PAI-2 are also able to express IL-1 or TNF, suggest a role for PAL2 in inflammation. PA1 2 could be involved in protection from inflammatory stress by inhibition of u-PA-dependent pericellular proteolytic processes either through the secretion of glycosylated PAI-2 or through the release of intracellular stores of nonglycosylated PAI-2. In this context, it is important to note that PAI-2 is much more resistant to oxidation than PAI-1, alpha 1 -proteinase inhibitor, or alpha 2-antiplasmin,2J" and would, therefore, be relatively resistant to freeradicals generated at the site of inflammation.
Rheumatoid arthritis and osteoarthritis. Fibrin deposition in the inflamed synovium is a feature of rheumatoid disease241 and implies an imbalance in the regulation of plasmin-mediated proteolysis. Imbalance in the opposite direction, an excess of proteases, may lead to the observed cartilage damage in rheumatoid arthritis (RA) and osteoarthritis (OA). U-PA has been detected in synovial fluid of patients with RA.242-244 Its level was correlated with the severity of For personal use only. on August 18, 2017. by guest www.bloodjournal.org From &tis, being highest in seropositive RA. 2453246 The Consistently elevated U-PA levels in RA synovial fluid suggests that this molecule is generated within the joint. Furthermore, in OA cartilage an increase of U-PA and of plasmin activity and a decrease of PAL1 was observed.x7 An increase of PAI-2 has also been reported in RA synovial f l~i d , '~~~'~~~~' SO the U-PA/PAI-2 balance may be one critical factor in RA joint damage.
Liver disease. There are occasional cases of elevated PAI-2 in liver disease, in particular two cases with hepatocarcinoma and several cases with cirrhosis.249~2s' The results presently available do not support the idea of PAI-2 as a candidate oncofetal marker for liver carcin0rna.2~' It is possible, however, that more sensitive PAI-2 antigen assays would detect small increases over a lower background level. Thus, small but significantly increased levels of PAI-2 were observed in 10 of 12 patients with alcoholic cirrhosis, 2 of 5 with primary biliary cirrhosis, and 2 of 4 with hepatic malignan~ies.2~' Disseminated intravascular coagulation. This condition is characterized by circulating fibrin(ogen) degradation products, including the fragment D-dimer, which may increase PAI-2 expression in monocyte-like
The increase of IL-1, which was also observed in these studies, might have been responsible for the increase of PAI-2.
Alzheimer's disease. Akiyama et detected higher levels of PAI-2 by immunohistochemistry in microglia from patients with Alzheimer's disease than from controls, with particularly dense staining around senile plaques. It is interesting to note that the amyloid beta-protein precursor contains a protease inhibitor domain, which like PAI-2, has an arg-~pecificity.'~~ Ophthalmic disease. Urokinase and t-PA are present at varying degrees in different structures of the normal eye. 255 Corneal ulceration, superficial keratitis, and other eye traumas are accompanied by the appearance of active PA?56-26i There is some correlation between U-PA activity and the severity of the disease and the application of the protease inhibitor aprotinin lowers plasmin activity and improves healing,262,263 which suggest that uncontrolled local PA activity could lead to epithelial defects and stromal ulceration. A preliminary study on the use of PAI-2 in the treatment of ophthalmic wounds has been reported.'" Rabbit eyes were subjected to alkali bum, repeated deepithelialization or corneal incision, and then treated with PAI-2. In controls, plasmin activity in lachrymal fluid increased sharply to 1 pg/ mL, or more, whereas in PAI-2-treated eyes, plasmin never exceeded 0.5 pglmL. In addition, PAI-2 prevented ulceration, inhibited neovascularization, suppressed inflammation of the cornea and stroma, and restored transparency of the eyes, thereby greatly improving healing from these injuries.
Apoptosis. A recent intriguing finding was that PAI-2-transfected HT-1080 cells were more resistant to TNF-mediated cytolysis than untransfected cells."' Also, an intracellular active, but cleaved 37 kD isoform of PAI-2, was detected during apoptosis in human NB4 cells and in homogenates made from leukemic cells aspirated from patients with acute and chronic myeloid 1e~kemia.I~' These observations suggest the existence of an intracellular proteinase, sensitive to PAI-2, which is involved in TNF-mediated cytolysis and in apoptosis.
PERSPECTIVES
Physiologic role of PAI-2. The amount of information on PAI-2 recently obtained, including kinetic data, cell localization, molecular expression and regulation, gene structure and its association with pregnancy, skin differentiation and disease, inflammation, and cancer is highly suggestive of an important role for PAI-2 in many physiologic and pathologic processes. Also, we should not discount the possibility that the physiologic activities of this serpin may be dependent on its cellular localization.
The secreted form of PAI-2 may contribute to the regulation of U-PA or t-PA activity on cell surfaces and in the pericellular space. Inflammatory agents induce not only PAI-2, but also U-PA and the U-PA receptor. This ensures an increase of cell-surface associated proteolytic activity and may enable monocytes/macrophages and other cell types to pass through tissue boundaries. The simultaneous induction of PAL2 release into the pericellular space may provide a means to further confine U-PA activity to the cell surface, thus enabling efficient passage of cells, while minimizing damage in the immediate surroundings. Secreted PAI-2 may also play important roles in controlling appropriate extracellular matrix remodeling during pregnancy and skin development. These activities invoke the classical serpin activity ascribed to PAI-2.
The role of PAI-2 close to the cell surface is more circumspect because few studies have addressed this topic. Targeting of PAL2 to the surface of migrating cells (eg, monocytes, neutrophils, T-cells, or other) would provide an attractive means of limiting cell migration by inhibition of U-PAR bound U-PA activity.
As to the function of intracellular PAI-2, one can only speculate at present. No intracellular target has been identified as yet for PAI-2, and in view of the efficient inhibition of U-PA and two chain t-PA, we may assume that one major role of intracellular PAL2 is to block PA-dependent proteolysis in the pericellular space after release from intracellular stores. After suitable stimulation PAL2 may represent up to several percent of total cell-associated protein, which provides a local storage pool of inhibitory activity and may be released under conditions of cell damage or apoptosis. A similar situation is encountered with L-l, which has no classical signal s e q u e n~e . *~.~~~ Release of large amounts of PAI-2 during cell death (or by as yet unidentified alternative mechanisms) could block local PA-dependent proteolytic activity and contribute to the encapsulation of the necrotic, inflammatory region as seen with PAL2 transfected tumor cells injected into
The inhibition of PA activity in the pericellular region not only would inhibit extracellular matrix degradation, but may also affect the proteolytic activation of growth factors and cytokines in the pericellular region. ' Some reports suggested a role for PAL2 as an inhibitor of TNF-mediated cytolysis or apoptosis and the observation of a cleaved form of PAI-2 in apoptotic cells suggest the presence of an intracellular target enzyme. The interpretation For personal use only. on August 18, 2017. by guest www.bloodjournal.org From of these studies is, however, not unequivocal and further work needs to be done to establish to what extent PAI-2 plays an essential or accessory protective role in apoptosis or cytolysis.
A powerful way to identify physiologic roles of PAI-2 is to determine whether there are developmental abnormalities or aberrant responses to inflammatory stimuli in PAI-2 "knock-out'' mice. As work in this direction is in an advanced stage (Belin and collaborators, University of Geneva, Ginsburg and collaborators, Ann Arbor, personal communications, 1995), one may hope to obtain further information on the physiologic role of PAL2 in the near future.
Therapeutic applications of PAI-2. In theory, PAI-2 has application to any disease in which abnormal expression of U-PA or t-PA has pathological consequences. Two factors are of critical importance. The first is the relative contribution of the PA system to the etiology and maintenance of the disease state. The second is the likelihood for PAI-2, a 46-kD protein, gaining access to the site of the lesion.
A large number of diseases and clinical conditions are associated with modifications of the PA system, in addition to those already mentioned in this review. with alpha 1 proteinase inhibitor were assayed in an organ culture model and in a mouse model for this disease. While all these agents prevented acantholysis in vitro, alpha 1 proteinase inhibitor was far more efficient in vivo than existing drugs.
Potentially, PAI-2 may find applications in anticancer therapy as an inhibitor of U-PA mediated as an inhibitor of angiogenesis, or as a cytotoxic targeting agent to tumor cells that express high levels of surface-bound u-PA. The rapid internalization of PAI-2:u-PA:u-PAR complexes should facilitate the cytotoxic action of radiolabeled PAI-2 or of conjugates of PAI-2 with cytotoxic agents. The usefulness of such an approach was shown by using a conjugate of PAI-I with the A-chain of cholera toxin, which was cytotoxic for a fibrosarcoma cell line.'7y
Taken together, there is enough evidence implicating u-PA and/or t-PA in disease to justify investigations into the usefulness of PAI-2 as a human therapeutic agent. PAL2 has several distinct advantages compared with PAI-1. First of all, in pregnant women (see above) sustained elevated PAL2 levels (at least up to 300 ng/mL) appear to have no systemic or pathologic consequences, whereas sustained elevations of PAI-I may be thrombogenic.280 Furthermore, PAI-2 is a stable protein, whereas PAI-I spontaneously loses sepsis,266.267 inflammatory bowel disease,26nR2hy appendiciits activity and is more sensitive to oxidation than PAI-2. Also, PAL2 is 10,000-fold less active toward single chain t-PA than PAI-I, which allows for a larger window of efficient U-PA inhibition, while preserving the antithrombotic potential of single chain t-PA in the blood circulation. Obviously the therapeutic value of PAL2 can only be established in animal models and in human trials. At present, the most promising prospects for PAI-2 as a therapeutic drug lie in its application to ophthalmic diseases.
Diagnostic applications of PAI-2. There are a number of possible diagnostic uses for PAI-2. The observations in preeclampsia and intrauterine growth retardation discussed above, where increased PAI-I is a marker for placental infarction and decreased PAL2 a marker of impaired placental function, needs further investigation. The good discrimination between preeclamptic and nonpreeclamptic individuals by using the PAI-l/PAI-2 ratio suggests the utility of such measurements.'hh To what extent measuring PAI-2 would provide a better diagnosis or prediction of complications of pregnancy than the presently known markers2*' remains to be established. Other obstetric and gynecologic conditions show aberrations of PAI-2 that may potentially be diagnostic. Elevated PAL2 has been reported in the plasma of some women investigated for recurrent miscarriage*" and in fluids from both malignant and benign ovarian cysts.'66 PAI-2 may also have diagnostic use in cancer. As described above, PAI-2 levels in plasma may differentiate between different types of leukemia and possibly between different stages of myelomonocytic leukemia. The normalization of PAL2 during remission and the high levels of PAI-2 during relapse in patients with acute myelomonocytic leukemia or acute monoblastic leukemia should incite careful studies on PAI-2 as an early plasma marker for relapse. PAI-2 antigen levels in tumor extracts may be of prognostic value in breast cancer, colorectal cancer, and lung cancer (see "PAL2 in Cancer"). The reasons why in some cancer types elevated PAT-2 predicts a good prognosis and in other cancer types the opposite remain to be established. Larger studies, with carefully standardized methods of sample collection, processing, and assays are needed. Finally, the ability of PAI-2 to locate and bind invasive cells expressing high levels of U-PAh-PAR invites studies on PAL2 as a tumor/metastasis imaging agent.
CONCLUSIONS
In recent years a large body of information has been gathered on the biology, biochemistry, and clinical aspects of PAI-2, which suggests that this inhibitor is involved in many physiologic and pathologic processes. The precise role of PAL2 (eg, in placenta, in pregnancy plasma, in skin or in inflammatory conditions), the pathologic consequences of PAI-2 deficiencies, as well as the diagnostic and therapeutic possibilities of PAI-2, still remain to be established.
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